- Home
- KFS vs PRTC Comparison
KFS vs PRTC Comparison
Compare KFS & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KFS
- PRTC
- Stock Information
- Founded
- KFS 1989
- PRTC 2015
- Country
- KFS United States
- PRTC United States
- Employees
- KFS N/A
- PRTC N/A
- Industry
- KFS Property-Casualty Insurers
- PRTC Biotechnology: Pharmaceutical Preparations
- Sector
- KFS Finance
- PRTC Health Care
- Exchange
- KFS Nasdaq
- PRTC Nasdaq
- Market Cap
- KFS 437.4M
- PRTC 435.0M
- IPO Year
- KFS 1996
- PRTC N/A
- Fundamental
- Price
- KFS $14.59
- PRTC $17.26
- Analyst Decision
- KFS
- PRTC
- Analyst Count
- KFS 0
- PRTC 0
- Target Price
- KFS N/A
- PRTC N/A
- AVG Volume (30 Days)
- KFS 62.3K
- PRTC 2.3K
- Earning Date
- KFS 11-05-2025
- PRTC 08-28-2025
- Dividend Yield
- KFS N/A
- PRTC N/A
- EPS Growth
- KFS N/A
- PRTC N/A
- EPS
- KFS N/A
- PRTC 0.20
- Revenue
- KFS $119,287,000.00
- PRTC $6,391,000.00
- Revenue This Year
- KFS N/A
- PRTC N/A
- Revenue Next Year
- KFS N/A
- PRTC N/A
- P/E Ratio
- KFS N/A
- PRTC $8.46
- Revenue Growth
- KFS 12.05
- PRTC 1265.60
- 52 Week Low
- KFS $7.06
- PRTC $13.30
- 52 Week High
- KFS $16.80
- PRTC $24.99
- Technical
- Relative Strength Index (RSI)
- KFS 46.92
- PRTC 46.41
- Support Level
- KFS $14.22
- PRTC $17.63
- Resistance Level
- KFS $16.25
- PRTC $18.17
- Average True Range (ATR)
- KFS 0.58
- PRTC 0.21
- MACD
- KFS 0.01
- PRTC -0.07
- Stochastic Oscillator
- KFS 25.47
- PRTC 15.66
About KFS Kingsway Financial Services Inc. (DE)
Kingsway Financial Services Inc through subsidiaries operates in the extended warranty and business services industries in the United States. The company operates through segments namely, Extended Warranty and Kingsway Search Xcelerator. The Extended Warranty segment provides after-market vehicle protection services distributed by credit unions. The firm generates maximum revenue from the Extended Warranty segment in the form of Service fee and commission income.
About PRTC PureTech Health plc
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.